Acadian Asset Management LLC Sells 5,305 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Acadian Asset Management LLC trimmed its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,951,208 shares of the biopharmaceutical company’s stock after selling 5,305 shares during the quarter. Acadian Asset Management LLC owned approximately 4.04% of Puma Biotechnology worth $6,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Great Point Partners LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth approximately $4,734,000. Jump Financial LLC grew its stake in Puma Biotechnology by 131.7% during the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 32,510 shares during the period. SG Americas Securities LLC acquired a new stake in Puma Biotechnology during the first quarter worth approximately $57,000. O Shaughnessy Asset Management LLC grew its stake in Puma Biotechnology by 127.7% during the first quarter. O Shaughnessy Asset Management LLC now owns 77,081 shares of the biopharmaceutical company’s stock worth $409,000 after purchasing an additional 43,229 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in Puma Biotechnology by 99.9% during the second quarter. Assenagon Asset Management S.A. now owns 140,205 shares of the biopharmaceutical company’s stock worth $457,000 after purchasing an additional 70,060 shares during the period. 61.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research note on Friday, August 2nd.

Insider Buying and Selling at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 18,885 shares of Puma Biotechnology stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $3.27, for a total transaction of $61,753.95. Following the transaction, the chief executive officer now owns 7,085,435 shares of the company’s stock, valued at $23,169,372.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Alan H. Auerbach sold 21,920 shares of Puma Biotechnology stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $3.70, for a total transaction of $81,104.00. Following the sale, the chief executive officer now directly owns 7,063,515 shares in the company, valued at $26,135,005.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Alan H. Auerbach sold 18,885 shares of Puma Biotechnology stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $3.27, for a total value of $61,753.95. Following the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,263 shares of company stock valued at $286,469. Company insiders own 23.70% of the company’s stock.

Puma Biotechnology Trading Up 4.6 %

Shares of Puma Biotechnology stock opened at $2.50 on Thursday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. Puma Biotechnology, Inc. has a 52 week low of $2.13 and a 52 week high of $7.73. The stock has a 50 day moving average price of $3.14 and a two-hundred day moving average price of $4.11. The stock has a market capitalization of $122.63 million, a PE ratio of 7.58 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Puma Biotechnology had a return on equity of 18.36% and a net margin of 4.01%. The firm had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $43.99 million. During the same quarter last year, the firm posted $0.05 earnings per share. As a group, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.25 earnings per share for the current fiscal year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.